Vertex Pharmaceuticals Incorpor (VRTX) Financials
VRTX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 22.7 billion | 5.1 billion |
| 2023-09-30 | 21.7 billion | 5.2 billion |
| 2023-06-30 | 20.3 billion | 4.9 billion |
| 2023-03-31 | 19.0 billion | 4.5 billion |
VRTX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 118.5 million | 208.6 million |
| 2023-09-30 | 1.2 billion | 130.9 million |
| 2023-06-30 | 1.1 billion | 119.3 million |
| 2023-03-31 | 857.8 million | 122.4 million |
VRTX Net Income
Graph available only for supporters. Become a supporter to see it.
| Date | Net Income |
|---|---|
| 2023-12-31 | 968.8 million |
| 2023-09-30 | 1.0 billion |
| 2023-06-30 | 915.7 million |
| 2023-03-31 | 699.8 million |
VRTX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 11.2 billion | - | 808.4 million |
| 2023-09-30 | 11.9 billion | - | 744.7 million |
| 2023-06-30 | 11.2 billion | - | 767.6 million |
| 2023-03-31 | 10.4 billion | - | 789.2 million |
VRTX Shares Outstanding
VRTX Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 116.1 million | 821.8 million | 369.1 million | - |
| 2023-09-30 | 40.6 million | 810.0 million | 263.8 million | - |
| 2023-06-30 | 59.6 million | 785.7 million | 262.0 million | - |
| 2023-03-31 | 42.1 million | 742.6 million | 239.2 million | - |
VRTX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 2.5 billion | 368.0 million |
| 2023-09-30 | 2.5 billion | 318.7 million |
| 2023-06-30 | 2.5 billion | 308.6 million |
| 2023-03-31 | 2.4 billion | 266.9 million |
VRTX
Price: $410.24
52 week price:
Earnings Per Share: 13.87 USD
P/E Ratio: 32.17
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.1 million
Ebitda: 142.2 millionMarket Capitalization: 102.8 billion